Lexicon Pharmaceuticals Inc. LXRX) on Tuesday reported a loss of $64.8 million in its third quarter. On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 18 cents.

The deal is a boost to Lexicon, because the company was unlikely to try to sell Inpefa outside of the U.S. on its own, according to Jefferies’ Tsai. Meanwhile, the drug fits into plans by Viatris to ...

16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals ... “We are pleased to be working with Viatris, a company with strong cardiometabolic expertise, global commercial capabilities and a ...

In other recent news, Lexicon Pharmaceuticals has made significant strides in its operations. The company reported new findings from its Phase 3 SCORED clinical trial, indicating renal benefits of ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $10.00. The company’s shares ...

This deal with KLAY is the latest in a string of partnerships between UMG and various "responsible" AI music start-ups. By Kristin Robinson Senior Writer Universal Music Group has entered a ...

The Stillwater Cultural District will host LexiCon – a free popular culture ... at 7 p.m. The Stillwater Community Band will perform music from “Harry Potter,” “Star Wars,” “Star ...

We uphold a strict editorial policy that focuses on factual accuracy, relevance, and impartiality. Our content, created by leading industry experts, is meticulously reviewed by a team of seasoned ...

By Jessica Nicholson Strategy, communications, integrated marketing and social impact consulting firm The Lede Company has launched a music division in Nashville, the company tells Billboard.

Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX), a biopharmaceutical company, has entered into an exclusive licensing agreement with Viatris Inc (NASDAQ:VTRS). for the development and ...